comparemela.com

Latest Breaking News On - Steatohepatitis consortium - Page 1 : comparemela.com

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

/PRNewswire/ DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate update..

United statesPaul gaglioJamese brownDrug administrationExchange commissionCorporation nasdaqSteatohepatitis consortiumInnocoll pharmaceuticals ltdInnocoll pharmaceuticalsEarnings call todayBusiness highlightsOpinion leaderBrett fortuneAmerican journalDefeat alcoholic steatohepatitisFast track designation

DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis

/PRNewswire/ DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic modulator programs for the treatment of acute.

United statesUniversity of california san diegoJamese brownCraig mcclainTarek hassaneinUniversity scholar at of louisvilleDrug administrationInnocoll pharmaceuticalsSouthern california research centerSteatohepatitis consortiumInnocoll pharmaceuticals ltdExchange commissionCorporation nasdaqAmerican journalDefeat alcoholic steatohepatitisObservational arm

vimarsana © 2020. All Rights Reserved.